## Phospho-PRAS40 (Thr246) Antibody





Orders:	877-616-CELL (2355) orders@cellsignal.com
Support:	877-678-TECH (8324)
Web:	info@cellsignal.com cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

For Research Use Only. Not for Use in Diagnostic Procedures.

Applications: W	<b>Reactivity:</b> H M R Mk	<b>Sensitivity:</b> Endogenous	<b>MW (kDa):</b> 40	<b>Source/Isotype:</b> Rabbit	UniProt ID: #Q96B36	Entrez-Gene Id: 84335		
Product Usage Information		ApplicationDilutionWestern Blotting1:1000						
Storage		Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 μg/ml BSA and 50% glycerol. 20°C. Do not aliquot the antibody.				ycerol. Store at –		
Specificity/Sensitivity		Phospho-PRAS40 (Thr246) Antibody detects endogenous levels of PRAS40 protein only when phosphorylated at Thr246.						
Source / Purifi	cation	Polyclonal antibodies are produced by immunizing animals with a synthetic phosphopeptide corresponding to the sequence surrounding Thr246 of human PRAS40. Antibodies are purified by peptide affinity chromatography.						
Background		Many growth factors and hormones induce the phosphoinositide 3-kinase signaling pathway, which results in the activation of downstream effector proteins such as the serine/threonine kinase Akt (1,2). One known Akt substrate is a 40 kDa, proline-rich protein (PRAS40) that binds to 14-3-3 proteins (2). PRAS40 also binds mTOR to transduce Akt signals to the mTOR complex. Inhibition of mTOR signaling stimulates PRAS40 binding to mTOR, which in turn inhibits mTOR activity (3). PRAS40 interacts with raptor in mTOR complex 1 (mTORC1) in insulin-deprived cells and inhibits the activation of the mTORC1 pathway mediated by the cell cycle protein Rheb. Phosphorylation of PRAS40 at Ser183 (5).						
Background R	eferences	1. Cantley, L.C. (2002) <i>Science</i> 296, 1655-7. 2. Kovacina, K.S. et al. (2003) <i>J Biol Chem</i> 278, 10189-94. 3. Vander Haar, E. et al. (2007) <i>Nat Cell Biol</i> 9, 316-23. 4. Sancak, Y. et al. (2007) <i>Mol Cell</i> 25, 903-15. 5. Oshiro, N. et al. (2007) <i>J Biol Chem</i> 282, 20329-39.						
Species Reacti	vity	Species reactivity is determined by testing in at least one approved application (e.g., western blot).						
Western Blot E	Buffer	IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.						
Applications K	ley	W: Western Blotting						
Cross-Reactivi	ty Key	H: Human M: Mouse R: Rat Mk: Monkey						
Trademarks and Patents		Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.						
		All other trademarks more information.	are the property of	their respective owners.	Visit cellsignal.com	/trademarks for		
Limited Uses		Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.						
		approved, cleared, or purpose. Customer sl any manner that conf	licensed by the FDA nall not use any Pro flicts with its labelin	se Only or a similar labe or other regulatory for duct for any diagnostic o g statement. Products so research and developme	eign or domestic er or therapeutic purp old or licensed by C	ntity, for any ose, or otherwise in ST are provided for		

diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.